Protherics Plc (Other) (6-K)
October 01 2007 - 10:53AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
28 September 2007
PROTHERICS PLC
(Translation of Registrants Name Into English)
The Heath Business & Technical Park
Runcorn, Cheshire, W47 4QF England
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F
X
Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 191(b)(7):
Indicate by check mark whether the registrant by furnishing the information contained
in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
Yes
No
X
If Yes is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2(b): 82-
.
The Registrant is furnishing a
copy of its announcements as reported to the Company Announcements Office of the London Stock Exchange.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
PROTHERICS PLC
|
|
|
|
|
|
|
|
Date: 28 Septeber 2007
|
|
By:
|
|
/s/ Rolf Soderstrom
|
|
|
|
|
Rolf Soderstrom
|
|
|
|
|
Finance Director
|
Protherics PLC
Total Voting Rights and Share Capital
London, UK; Brentwood, TN; 28 September 2007 - In conformity with the
Transparency Directive, Protherics PLC ("Protherics"), the international
biopharmaceutical company focused on critical care and cancer, notifies the
market of the following:
Protherics' issued share capital consists of 339,316,822 ordinary shares with a
nominal value of 2 pence each, with voting rights. Protherics does not hold any
ordinary shares in Treasury. Therefore, the total number of voting rights in
Protherics is 339,316,822.
The above figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, Protherics under the Financial
Services Authority's Disclosure and Transparency Rules.
| Ends |
For further information please contact:
Protherics
Nick Staples, Director of Corporate Affairs +44 (0) 7919 480510
Julie Vickers, Company Secretary +44 (0)1928 518010
Financial Dynamics - press enquiries
London: Ben Atwell, David Yates +44 (0) 20 7831 3113
New York: John Capodanno, Jonathan Birt +1 212 850 5600
Or visit www.protherics.com
Protherics (NASDAQ:PTIL)
Historical Stock Chart
From May 2024 to Jun 2024
Protherics (NASDAQ:PTIL)
Historical Stock Chart
From Jun 2023 to Jun 2024